Healthcare -
Biotechnology - NASDAQ - US
$ 3.46
-9.06 %
$ 37.3 M
Market Cap
-1.61
P/E
1. INTRINSIC VALUE
Balance Sheet
Lantern Pharma Inc.
| Current Assets | 25.2 B |
| Cash & Short-Term Investments | 24 B |
| Receivables | 0 |
| Other Current Assets | 1.23 B |
| Non-Current Assets | 324 M |
| Long-Term Investments | 0 |
| PP&E | 287 M |
| Other Non-Current Assets | 36.7 M |
| Current Liabilities | 4.33 B |
| Accounts Payable | 0 |
| Short-Term Debt | 191 K |
| Other Current Liabilities | 4.33 B |
| Non-Current Liabilities | 52.8 M |
| Long-Term Debt | 52.8 K |
| Other Non-Current Liabilities | 52.8 M |
EFFICIENCY
Earnings Waterfall
Lantern Pharma Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 22.2 B |
| Operating Income | -22.2 B |
| Other Expenses | -22.2 B |
| Net Income | -20.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Lantern Pharma Inc.
| Net Income | -20.8 M |
| Depreciation & Amortization | 0 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 0 |
| Change in Working Capital | 2.23 M |
| Others | 2.97 M |
| Free Cash Flow | -17.8 M |
Wall Street Analysts Price Targets
Lantern Pharma Inc.
LTRN has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
LTRN does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Lantern Pharma Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
378 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 AM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Conference Call Participants Operator Good afternoon, and welcome to our Fourth Quarter and Year End 2024 Earnings Call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.
seekingalpha.com
- 1 month ago
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an update on its portfolio of AI-driven drug candidates, the RADR® platform for precision oncology drug.
businesswire.com
- 1 month ago
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Q4 & Fiscal Year 2024 Earnings Call Save The Date.
businesswire.com
- 1 month ago
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced that the first patient has been enrolled and dosed in Taiwan for its Phase 2 HARMONIC™ clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with tyrosine kinase inhibitors (TKIs). The enrollment of the first patie.
businesswire.com
- 4 months ago
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Triple Negative Breast Cancer (TNBC). This marks the second Fast Track Designation received for LP-184 in 2024, following its designation for.
businesswire.com
- 4 months ago
Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence company transforming oncology drug development, and its wholly-owned subsidiary Starlight Therapeutics, focused exclusively on CNS and brain cancers, today announced the presentation of new preclinical data and Phase 1b trial design for LP-184 (to be developed as STAR-001 for CNS indications) in glioblastoma at the Society for Neuro-Oncology (SNO) 2024 Annual Meeting in Houston, Texas. The poster presentatio.
businesswire.com
- 5 months ago
Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript
Lantern Pharma Inc. (NASDAQ:LTRN ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Panna Sharma - President and CEO David Margrave - Chief Financial Officer Kishor Bhatia - Chief Scientific Officer Operator Good afternoon, and welcome to our Third Quarter 2024 earnings call. As a reminder, this call is being recorded, and all attendees are in a listen-only mode.
seekingalpha.com
- 5 months ago
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the third quarter 2024, ending September 30, 2024. "Lantern is achieving remarkable momentum, balancing meticulous execution with innovation. While progressing on.
businesswire.com
- 5 months ago
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
DALLAS--(BUSINESS WIRE)--Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the formation of a Scientific Advisory Board (“SAB”) to support the development of lead compound STAR-001. The inaugural SAB will work closely with Starlight's management team to provide strategic guidance and critical expert insights into the development of STAR-001 in CNS and bra.
businesswire.com
- 5 months ago
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2024 operating and financial results webcast on Thursday, November 7, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial.
businesswire.com
- 6 months ago
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern management will be presenting at the ThinkEquity Conference on Wednesday, October 30, 2024, at 10:30 a.m. ET at the Mandarin Oriental in New York, NY. Webcast Link: https://www.meetmax.com/sched/event_106721/conference_register.html Confe.
businesswire.com
- 6 months ago
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Glioblastoma. LP-184 is currently in a Phase 1A clinical trial designed to evaluate the safety and tolerability of the synthetically lethal in.
businesswire.com
- 6 months ago
8. Profile
Summary
Lantern Pharma Inc. LTRN
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 37.3 M
Dividend Yield
0.00%
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Contact
1920 McKinney Avenue, Dallas, TX, 75201
https://www.lanternpharma.com
IPO
Date
June 11, 2020
Employees
24
Officers
Mr. Panna Sharma
President, Chief Executive Officer & Director
Dr. Marc C. Chamberlain M.D.
Chief Medical Officer of Starlight Therapeutics
Mr. David R. Margrave
Chief Financial Officer & Secretary
Dr. Kishor Gopaldas Bhatia Ph.D.
Chief Scientific Officer & Scientific Consultant
Dr. Peter L. Nara D.V.M., M.S., Ph.D.
Co-Founder & Advisor
Mr. Ernest Kitt B.S., M.S
Head of Clinical Operations